pharma · Prostate Cancer · Myelodysplastic Syndromes · SNSE
Sensei Biotherapeutics
Sentinel BioTherapeutics is a pharma organization headquartered in ROCKVILLE, MD, USA. It trades on NYSE under ticker SNSE. Primary therapeutic focus areas include Prostate Cancer, Myelodysplastic Syndromes, Squamous Cel
ROCKVILLE, MD, USA HQ
2 Employees
Public company Type
SNSE · NYSE Ticker
Company details
- Status
- Public
- HQ
- ROCKVILLE, MD, USA
- Employees
- 2
- Programs
- 3
- Drugs
- 0
- Patents
- 1
SNS-301
Phase 2 · small molecule · Myelodysplastic Syndromes
SNS-301 for Myelodysplastic Syndromes is a Phase 2 program (small_molecule) at Sensei Biotherapeutics with 1 ClinicalTrials.gov record(s).
Internal code SNS-301-2-1
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sensei Biotherapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Myelodysplastic Syndromes
- Status
- terminated
- Trials
- 1